Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 18,156
- Companies
- 1,062
- Drugs tracked
- 3,385
Quick answer
NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
18F-92
First Tracks Biotherapeutics
Alzheimer's Disease
1 trial -
2 cycles of combined drug induction therapy: every 3 weeks for 2 cycles; After ,synchronous radiotherapy and chemotherapy combined immunotherapy
First Tracks Biotherapeutics
Cervical Cancer Stage IVA
1 trial -
225Ac-LNC1011
First Tracks Biotherapeutics
Prostate Cancer
1 trial -
3D hypoxia-preconditioned UC-MSC group
First Tracks Biotherapeutics
Severe Aplastic Anemia (SAA)
1 trial -
68Ga-DOTATATE and 68Ga-FAPI
First Tracks Biotherapeutics
Tumor Positron-Emission Tomography
1 trial -
68Ga-FAP-CHX
First Tracks Biotherapeutics
Tumor
1 trial -
68Ga-G21
First Tracks Biotherapeutics
Prostate Cancer (Adenocarcinoma)
1 trial -
68Ga-NY104 PET/CT
First Tracks Biotherapeutics
Clear Cell Renal Cell Carcinoma
1 trial -
AK104, nab-paclitaxel, carboplatin
First Tracks Biotherapeutics
Esophageal Squamous Cell Carcinoma
1 trial -
AK105 and anlotinib
First Tracks Biotherapeutics
Cervical Cancer
1 trial -
ASC22
First Tracks Biotherapeutics
Chronic Hepatitis b
1 trial -
Abatacept s.c.
First Tracks Biotherapeutics
Abatacept
1 trial -
Absorbable and moldable skull base support plate
First Tracks Biotherapeutics
Sellar Tumor
1 trial -
Ad-HGF
First Tracks Biotherapeutics
Myocardial Infarction
1 trial -
Adebellizumab
First Tracks Biotherapeutics
Resectable Lung Non-Small Cell Carcinoma
1 trial -
Adebrelimab combined with irinotecan liposomal (II), oxaliplatin, and 5-FU/LV
First Tracks Biotherapeutics
Pancreatic Cancer
1 trial -
Adebrelimab+Albumin paclitaxel +Cisplatin
First Tracks Biotherapeutics
Locally Advanced Hypopharyngeal Cancer
1 trial -
Adebrelimab, paclitaxel, carboplatin, bevacizumab, fluzoparib
First Tracks Biotherapeutics
Platinum-sensitive Relapsed Ovarian Cancer
1 trial -
All-trans Retinoic Acid in combination with the KPD Regimen
First Tracks Biotherapeutics
Multiple Myeloma in Relapse
1 trial -
Almonertinib
First Tracks Biotherapeutics
Non Small Cell Lung Cancer
1 trial -
Almonertinib
First Tracks Biotherapeutics
EGFR Positive Non-small Cell Lung Cancer
1 trial -
Ametinib combined with bevacizumab
First Tracks Biotherapeutics
Non-small Cell Lung Cancer
1 trial -
Anlotinib
First Tracks Biotherapeutics
Non-Small-Cell Lung Cancer
1 trial -
Anlotinib Hydrochloride
First Tracks Biotherapeutics
Effect of Drugs
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources